Announcements Trials
Browse Landscape

Phase

Phase 2 60Phase 1 19Phase 3 17Phase 1/2 16Phase NA 6Phase 2/3 5Phase 4 2Phase EARLY_PHASE1 1

Status

Completed 9Unknown 5Recruiting 5Active not recruiting 5Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Gemcitabine 12Dexamethasone 12Magnetic Resonance Spectroscopy 10Bevacizumab 10venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Docetaxel 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7130-nm albumin-bound paclitaxel 7Methotrexate 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Cytarabine × Clear all
NCT06788756 2026-04-29

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Moleculin Biotech, Inc.

Phase 2/3 Recruiting
312 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06855810 2025-08-26

CCCG-TALL-2025

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
610 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06882057 2025-08-26

CCCG-LR-B-ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
3,000 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05939180 2024-04-09

VA vs DA for Newly Diagnosed Hig-risk AML

The First Affiliated Hospital of Soochow University

Phase 2/3 Recruiting
116 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05805098 2023-04-07

VHA

The First Affiliated Hospital of Soochow University

Phase 2/3 Recruiting
60 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡